Employees: 489
Size Ardelyx (ARDX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $784M, the 2385th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.12 on 18 Nov 2026.
Performance Over six months the shares fell 50.2%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue grew 17.6% over the last twelve months (peer median +5.2%); the operating margin is -7.7% (peer median 12.0%).
Valuation It trades at 252.9× forward earnings against a peer median of 10.8× (most expensive of 8).
Capital Return on invested capital runs 29.3 points below its cost of capital (8.1% WACC).
Short interest Short interest is 11.6% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $468M | $407M | $334M | $124M | $52.2M |
| Revenue growth | — | +22% | +168% | +139% | — |
| Gross profit | $439M | $365M | $281M | $105M | $43.4M |
| EBITDA | -$33.0M | -$37.9M | -$25.9M | -$62.0M | -$59.2M |
| Net income | -$55.5M | -$61.6M | -$39.1M | -$66.1M | -$67.2M |
| Free cash flow | -$16.0M | -$44.0M | -$45.8M | -$90.1M | -$70.1M |
| Capital expenditure | $443,000 | $1.49M | $1.01M | $344,000 | $55,000 |
| Total debt | $256M | $208M | $153M | $56.0M | $47.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ARDX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.8% | -1.0% | 10th highest of 19 |
| 6-month return | -50.2% | -4.7% | lowest of 19 |
| Distance from 52-week high | -62.9% | -31.2% | 2nd lowest of 19 |
| Revenue growth (TTM) | +17.6% | +5.2% | 6th highest of 19 |
| Operating margin | -7.7% | 12.0% | 4th lowest of 19 |
| Forward P/E | 252.9× | 10.8× | most expensive of 8 |
| ROIC minus cost of capital | -29.3 pp | +0.5 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 252.9× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | n/a | -2.5% | +2.6% |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | n/a | n/a | n/a |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | n/a | 33.9% | +10.1% |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 3.5× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 42.2× | 6.6% | +17.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 19.6× | 16.3% | -8.7% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 10.8× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 24.3× | 13.9% | +27.7% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | n/a | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | n/a | 0.3% | +0.5% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 3.7× | -2.6% | +20.3% |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | n/a | 13.5% | -0.2% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | n/a | 9.4% | -1.4% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | n/a | n/a | n/a |